乌干达已开始对新生儿进行镰状细胞筛查,但由于费用高昂和基础设施有限,在整个非洲,基因疗法仍然负担不起。 Uganda started newborn screening for sickle cell, but gene therapies remain unaffordable across Africa due to high costs and limited infrastructure.

乌干达在全国范围内启动了镰状细胞疾病的新生儿筛查,但在非洲各地,卡斯格维和莱夫根尼亚等挽救生命的基因疗法仍然负担不起,治疗费用高达220万美元。 Uganda has launched nationwide newborn screening for sickle cell disease, but life-saving gene therapies like Casgevy and Lyfgenia remain unaffordable across Africa, with treatments costing up to $2.2 million. 尽管美国和欧洲批准了这些基于CRISPR的治疗方法,但在撒哈拉以南非洲却无法获得这些治疗方法,那里80%的全球病例发生在该地区。 Though approved in the U.S. and Europe, these CRISPR-based cures are inaccessible in Sub-Saharan Africa, where 80% of global cases occur. 费用高昂、缺乏基础设施以及保健能力有限,阻碍了广泛使用,使大多数病人依赖基本、往往负担不起的护理。 High costs, lack of infrastructure, and limited healthcare capacity prevent widespread use, leaving most patients reliant on basic, often unaffordable care. 倡导者敦促采取全球行动,通过价格改革和对当地医疗能力的投资,确保公平准入。 Advocates urge global action to ensure equitable access through pricing reforms and investment in local medical capacity.